Moreover, the Kaplan–Meier method revealed a poor prognosis with lower SLC16A1-AS1 expression in BC patients, which was considerably related to decreased overall survival rate and disease-free survival rate, indicating that it was a possible prognostic factor and a therapeutic target for BC patients. This evidence concerns the gene SLC16A1 and breast cancer.